

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB05/000803

International filing date: 02 March 2005 (02.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB  
Number: 0405636.2  
Filing date: 12 March 2004 (12.03.2004)

Date of receipt at the International Bureau: 31 May 2005 (31.05.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



GB05/803



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.


In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

Andrew Gersey  
14 April 2005






12 MAR 2004

# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road  
Newport  
South Wales  
NP9 1RH

1. Your reference

PAC/eehc/22629 GB

2. Patent application number

(The Patent Office will fill in this part)

0405636.2

3. Full name, address and postcode of the or of each applicant (underline all surnames)

PAUL DOUGLAS CLARKE  
201 EAST DULWICH GROVE  
LONDON  
SE22 8SY

07319379001

Patents ADP number (if you know it)

UNITED KINGDOM

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

ANTIVIRAL COMPOSITION

5. Name of your agent (if you have one)

A A THORNTON & CO

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

235 HIGH HOLBORN  
LONDON WC1V 7LE

Patents ADP number (if you know it)

0000075001 ✓

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

YES


- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (d))

## Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description	8
Claim(s)	1
Abstract	1
Drawing(s)	-



10. If you are also filing any of the following, state how many against each item.

Priority documents	--
Translations of priority documents	--
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	--
Request for preliminary examination and search (Patents Form 9/77)	--
Request for substantive examination (Patents Form 10/77)	--
Any other documents (please specify)	--

11. I/We request the grant of a patent on the basis of this application.

Signature

A. A. Thornton & Co.

Date

12 MARCH 2004

12. Name and daytime telephone number of person to contact in the United Kingdom

Philip A. CURTIS - 020 7440 6860

### Warning

*After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.*

### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*

ANTIVIRAL COMPOSITION

The present invention relates to an antiviral composition.

It is known that a number of natural products have insect repellent properties.

5 Citriadora oil obtained from various species of eucalyptus is one example of such a natural product, citronella oil which is obtained from certain grasses is another. We have previously investigated certain insect repellent natural products and have found that the insect repellent properties are in a fraction rich in p-menthane-3,8-diol (PMD). This is described in our GB-A-2282534. In GB-A-1315625, there is described the use of  
10 certain p-menthane diols, but not PMD, to provide a physiological cooling effect. EP-B-1204319 describes the use of PMD as a general antiseptic. We have now found, very surprisingly, that PMD also possesses the totally unrelated quality of antiviral properties.

According to one aspect of the invention, we provide the use of PMD in the  
15 manufacture of a medicament for use as an antiviral agent.

It is to be understood that the term "virucidal" means any compound that destroys viruses. It is also to be understood that the term "anti-viral agent" means an agent which inhibits or stops the growth and reproduction of viruses, or which destroys viruses. The use of PMD in the present invention may be virucidal.

20 The PMD for use in the present invention may be derived from a natural source or may be synthetic, or a mixture of the two. A preferred source of natural PMD is the lemon eucalyptus plant. Synthetic PMD may be obtained by any route, for example, such as described by Zimmerman and English in J.A.C.S. 75 (1953) pp 2367-2370.


The PMD for use in the present invention may be a substantially pure form of the  
25 compound, or a crude extract, for example from a natural source. An example of a crude extract is a PMD-rich extract derived from lemon eucalyptus. The PMD can be produced by cyclisation of citronellal which is present in high concentration in lemon eucalyptus oil (approximately 75% by weight). We have obtained a PMD-rich extract from the lemon eucalyptus oil which includes both geometric isomers of PMD usually at  
30 about 64% by weight. The crude extract also includes citronellol and isopulegols plus certain other minor components.

According to a further aspect of the invention, there is provided the use of a PMD-rich extract containing composition, which extract is derived from natural lemon

eucalyptus oil, as an antiviral agent. An example of this sort of crude extract is available under the trade mark "Citriodiol".

A composition for use in accordance with the invention can comprise PMD and a carrier. PMD is poorly soluble in water, so that it is preferred to use an oil as a carrier,  
5 or use a solvent, such as alcohol, for waterbased compositions.

It is known that PMD exists in two geometric isomeric forms, namely the cis and trans isomers, and that there are two enantiomers for each geometric isomer.



10 Our experimental work is based on the 98% pure cis isomer. It will be understood, however, that the claimed activities for PMD are common to all its isomeric forms. Thus, the PMD may be used in the form of a single pure cis or trans isomer, or a mixture of the isomers, such as a 50-50 mixture of the isomers.

In a further aspect of the invention, the composition for use in the invention  
15 comprises only one of the isomers of PMD, with a carrier therefor.

It is a further aspect of the invention that the relative amounts of cis: trans PMD isomers in the compositions for use in the present invention are varied as desired. This can be done by mixing previously separated isomers in the appropriate ratio, or by adjusting the ratio in a mixture of naturally occurring or synthetic source.

20

In tests we have found that PMD is effective against an influenza virus A/Sydney/5/97. In a further aspect, therefore, the invention provides the use of PMD in the manufacture of a medicament for use as an antiviral agent against an influenza virus A/Sydney/5/97.

The uses of the present invention may be adopted in sanitizing a surface, for example in a hospital room or ward. In such cases PMD is applied to the surfaces. The PMD is preferably either in solution or as an emulsion in suitable liquid carriers. Most desirably, the PMD is formulated for spray application. For example, the PMD or  
5 Citriodiol can be dissolved in a suitable solvent or solvent mixture. For example, in one embodiment, the PMD may be provided in the form of a nasal spray; in another embodiment, the PMD may be provided in the form of a spray for telephones.

In a one mode of application, the spray is an electrostatic spray. For electrostatic spraying, the solvent or solvent system will need to be appropriate for electrostatic  
10 spraying, as will be clear to those skilled in the art. I prefer to use a mixture of conductive and nonconductive solvents to achieve a sprayable solution with the appropriate electrical resistivity for the spray nozzle in question, but suitable single solvents can of course be used. Charged particles of the composition including PMD are projected as a fine mist and because all the particles carry a similar, for example  
15 positive, charge they repel each other, but are attracted to an oppositely charged surface. By this means of spraying, a very good coverage of the composition on the surface may be obtained. Devices for electrostatically spraying the composition for use in the invention will be known to the person skilled in the art.

A spray may also be used, for example, for dispensing a composition including  
20 PMD onto a hand (or other part) of a person. The actuation of the dispenser may be by means of an infra-red sensor, for example, so that the person need not contact a surface, and thereby risk the transfer of microbes to or from their hand. Electrostatic spray application to a hand may be used, with advantage, where a substantially uniform coverage of antiseptic is particularly important e. g. to a surgeon during  
25 "scrubbing up" before surgery.

To increase the likelihood of the charged particles covering the skin surface, desirably the electrostatic spray nozzles may be arranged to spray into the interior of a cabinet or container as the hand is introduced therein.

The liquids for applying to a surface, by spraying or otherwise, in accordance  
30 with the invention may contain, apart from the solvent (s) and/or other liquid carrier (s), other components as necessary or desirable for the intended purpose. Thus, second or further antiviral agents may be included, as may surfactants, fragrances etc. In general, the compositions may be identical to known compositions for the purpose except that



they contain PMD in addition to, or in whole or part substitution for one or more of, the other ingredients.

The amount of PMD can vary widely. Although our tests have showed that PMD levels of 0.5% w/v and less impart no virucidal effect against influenza virus 5 A/Sydney/5/97, it may have an effect against other viruses at lower concentrations. PMD may also be included as an anti-viral agent in household detergents, cleansers and creams, for example, washing powders or conditioners and hand gels.

Again, the PMD may be included in what are otherwise standard or known compositions for the purpose concerned. The PMD may be an extra ingredient or in 10 partial or complete replacement of a standard ingredient. The compositions may already contain an antiviral agent and the PMD is added to give an extra anti-viral effect.

Furthermore, PMD may be impregnated into household objects which may be prone to microbial infestation and so risk infecting inhabitants, e. g. dishcloths, plastic 15 soap dishes, surfaces used for the preparation of food.

For these purposes, the PMD may be included during manufacture of the object, e. g. in mixtures for plastics mouldings or the like, or it may be applied to the object after manufacture, e. g. by soaking dishcloths in PMD. The presence of the PMD at the surface of the object will provide the desired antiseptic effect. This is particularly useful 20 for work surfaces, although of course such surfaces-can also be regularly treated with PMD as by spraying or otherwise.

A composition including PMD can also be used in medicine. For example, it can be applied to broken skin, or to internal mucous membranes. It may be an ingredient in throat lozenges or pastilles or other products for ingestion. In this aspect, the invention 25 provides PMD for use as an antiseptic, antibiotic, bactericide or fungicide. In medical uses the PMD may be formulated with the carrier as a cream, or, as mentioned above, as a throat lozenge or pastille. A composition including PMD may be applied to the accessible inner surfaces of the nose in order to control or eliminate viruses which may cause regular systemic effects. Another specific medical use is in wound irrigation 30 during surgery, e. g. surgery conducted on the peritoneal cavity.

As will be evident to those skilled in the art, there are a very large number of medical uses of PMD as an antiviral or virucidal agent. In general, new formulations for these purposes are not required: it is adequate and satisfactory to take a known or

standard composition and include the PMD therein. Alternatively, one or more ingredients may be replaced by the PMD as appropriate. Those skilled in the art will well know the make-up of the various compositions and no further particular description thereof is given here.

5 PMD is the active ingredient in the insect repellent sold under the trade name "Mosiguard"<sup>TM</sup>. Tests have already been conducted show regulatory authorities that PMD is not toxic, and the Mosiguard insect repellent has been marketed for several years and there has been no report of any significant toxicity thereof. Potentially, therefore, the medical uses of PMD may be topical or systemic. Systemic  
10 administration may be by way of an oral dosage form or by a parenteral route, such as by intra-venous injection.

In general, PMD is used in accordance with the invention in a wide variety of vehicles, depending on the particular use intended. The vehicles may, for example, include solids, liquids, emulsions, foams and gels.

15 Typical vehicles include aqueous or alcoholic solutions, oils, fats, fatty acid esters, long chain alcohols and silicone oils, finely divided solids such as starch or talc, cellulosic materials and aerosol propellants. Topical compositions include perfumes, powders and other toiletries, lotions, liniments, oils and ointments, for example. Toiletries generally include after shave lotions, shaving soaps, lipstick, creams, foams,  
20 toilet water, deodorants, antiperspirants, solid colognes, toilet soaps, bath oils and salts, shampoos, face and hand creams, cleansing tissues, mouthwashes, eye drops, for example. Medicaments and allied compositions include, for example, ointments, lotions, decongestants and throat lozenges. The amount of PMD present in the compositions will be selected to give the desired effect but we believe that generally up  
25 5.0 wt%, preferably from 0.1 to 5.0 wt % will be satisfactory. Greater amounts can be used. A particularly preferred concentration is from 1.0 to 3.0wt%. especially about 2 wt%.

A PMD-rich extract may be obtained from PMD-containing material, such as the leaves of a eucalyptus plant. A preferred source of PMD rich extract is obtained by  
30 stirring eucalyptus citriadora oil derived from the plant with dilute sulphuric acid (usually 5% sulphuric acid), as previously explained in our GB-A-2282534.

In order that the invention may be fully understood, the following Procedures are given by way of illustration only.

Procedure 1**Procedure for the acute toxicity assay of PMD**

The toxicity of PMD at the following concentrations in cell maintenance media was  
5 determined on a cell line with MDCK cells:

- 2.5mg/ml (0.25% w/v)
- 5mg/ml (0.5% w/v)
- 20mg/ml (2% w/v)

10 A cell only control was also implemented by following the same procedure (steps 2-6),  
but substituting PMD with cell maintenance media.

Toxicity was determined by toxicity-induced CPE (cytopathic effect) observations,  
which was visually scored using microscopy techniques. Toxicity-induced CPE is  
15 characterised by burst or rounded cells, which have become dissociated from their  
neighbouring cells, or the presence of cellular debris. Toxicity-induced CPE was  
scored as positive (toxicity observed) or negative (no toxicity observed).

- 20 (1) 200µl of each PMD dilution was added to 200µl of cells (at  $2 \times 10^6$  cells/ml)  
and the reaction incubated for 5 minutes at room temperature.
- (2) The reaction was terminated by adding 3.6mls of cell maintenance media  
appropriate to the cell line.
- 25 Note: termination of the reaction is due to the addition of cell maintenance  
media, which dilutes the reaction 10-fold.
- (3) 100µl of the terminated reaction was added to the relevant wells on 48-well  
plates and incubated for 24 hours at 37°C, 5% CO<sub>2</sub>.

30

Note: the remaining terminated reaction was measured for levels of pH.

- (4) The cells in the 48-well plate were typsinised and a viable cell count was performed using the Trypan blue dye. The percentage of viable cells was used to determine the toxic concentration of PMD in comparison to the cells only contr

5

10

## Procedure 2

### **Procedure for the virucidal assay of PMD**

- 15 The virucidal assay was carried out using four different concentrations of PMD, which do not exhibit toxicity (based on the data obtained from the procedure described in 1).

The four concentrations are summarised in the following table.

20

Concentration (w/v)	0.1	0.25	0.5	2
Concentration (mg/ml)	1	2.5	5	20

The stock virus was used at a titre greater than  $10^4$  TCID<sub>50</sub>/ml.

- 25 The appropriate positive anti-viral control compound was citric acid.

The presence and absence of viral infection was determined by infection-induced CPE observation, which was visually scored using microscopy techniques. Infection-induced CPE differs between viruses, but is normally characterised by ballooning or rounded  
30 cells that remain attached to their neighbouring cells. It was scored as positive (infection apparent) or negative (infection not apparent).

- (1) MDCK cell lines were cultivated according to the current Retroscreen Virology Ltd. SOP onto 96-well plates.
- 35 (2) 40µl of A/Sydney/5/97 virus was added to 360µl of each PMD dilution and citric acid.

Note: The virus was diluted 10-fold in this step.

- 5 (3) The reactions were incubated at room temperature for the following contact times:
- a. 10 seconds
  - b. 30 seconds
  - c. 1 minutes
  - 10 d. 5 minutes
- (4) At each contact time point, the reaction was terminated by adding 3.6ml of infection media appropriate to the cell line.
- 15 Note: termination of the reaction is due to the addition of infection media, which dilutes the reaction 10-fold.
- 20 (5) 100µl of the terminated reaction was added to the first column of 96-well plates (prepared in point 1) and titrated across the plate following a 1/10 dilution series.
- Note: the remaining terminated reaction was measured for levels of pH.
- 25 (6) The cells were incubated for 3-5 days at 37°C, 5% CO<sub>2</sub>.
- (7) CPE was scored daily on the plates to determine the presence or absence of infection. The reduction in viral titre (as a result of anti-viral activity of PMD and the positive control compound, citric acid) was determined.
- 30 The results showed that using an influenza virus A/Sydney/5/97 on MDCK cells, there was no viral replication as evidenced by cell survival with 2% w/v PMD in the culture medium. At lower concentration (0.5%, 0.25% and 0.1%) cells were killed indicating no virucidal effect at these levels.

**CLAIMS**

1. The use of p-menthane-3,8-diol (PMD) for the manufacture of a medicament for use as an antiviral agent.

5

2. The use of PMD as an anti-viral agent in non-therapeutic, non-surgical and non-diagnostic applications.

3. The use according to claim 1, wherein the PMD is used to treat influenza virus  
10 A/Sydney/5/97.

4. The use of PMD to denature influenza virus A/Sydney/5/97.

5. The use of PMD to denature viruses.

15

6. The use according to any preceding claim, wherein the PMD is a crude or purified natural product or is a synthetic product.

7. The use according to any preceding claim, wherein the PMD is provided in the  
20 form of PMD-rich extract derived from lemon eucalyptus.

8. The use according to any preceding claim, wherein the PMD is provided in the form of a spray.

25 9. The use according to any preceding claim, wherein the PMD is provided in the form of a composition comprising PMD and a carrier.

10. The use according to any preceding claim, wherein the amount of PMD in the composition is at least 0.5% w/v.

30

11. The use of PMD substantially as herein described with reference to and as shown in the examples.

**ABSTRACT**  
**ANTIVIRAL COMPOSITION**

- 5 The use of p-menthane-3,8-diol (PMD) as an antiviral agent.





